Article info
Therapeutics/Prevention
Randomised controlled trial
Clinicians should assess the benefits and risks of using bezlotoxumab for reducing the risk of recurrent Clostridium difficile infection
- Correspondence to Dr Abhishek Deshpande, Medicine Institute Center for Value-Based Care Research, G10, Cleveland Clinic, Cleveland, OH 44195, USA; abhishekdp{at}gmail.com
Citation
Clinicians should assess the benefits and risks of using bezlotoxumab for reducing the risk of recurrent Clostridium difficile infection
Publication history
- First published July 17, 2017.
Online issue publication
July 26, 2017
Article Versions
- Previous version (17 July 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.